WIKIFARMER
23.6.2022 10:02:13 CEST | Business Wire | Press release
Wikifarmer , a global platform with the mission of empowering farmers through educating them and offering them access to the open market to sell their products at fair prices and mentioned as the “Wikipedia of Farming” by the FAO of the UN, has successfully completed a Seed financing round with the support of a group of world class investors such as Mathias Kamprad, Inter IKEA BoD, Patrick and Cynthia Odier of the Lombard Odier Private Bank, Sophia Bendz, venture capitalist and former Spotify global director of marketing, Alexandre Vilgrain, C.E.O. of SOMDIAA group, the Constantakopoulos foundation and with the participation of Metavallon Venture Capital, a leading Greek VC firm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005694/en/
Agriculture is still one of the least digitized industries in the world and this has not allowed the industry’s value chain to be disrupted, but instead has created a paradox; farmers are the most valuable part of agriculture’s value chain but make the least profit out of it. In addition to that, most farmers are still using the techniques of their ancestors to grow their crops. The need for up-to-date sustainable agriculture knowledge has never been greater in the world than today. Agriculture & food trade market is expected to exceed 6 trillion EUR in value by the end of 2025.
Wikifarmer’s platform allows farmers to access free up to date knowledge on agricultural best practices and gives them the opportunity to sell their products directly to businesses, helping them minimize or surpass the large number of intermediaries that currently exist. Wikifarmer is aiming to become the universal source for farmers searching for information and the go-to destination for people seeking to purchase agricultural products globally.
Co-founders Ilias Sousis, Peter Sagos and Harry Parianos were inspired by the negative impact that outdated practices in agriculture have on the environment, global hunger and the financial sustainability of farmers. At the same time, helping farmers make a higher profit margin out of their commercial activities will have a wider impact on the economy and on the quality of products produced.
Sousis has been a part of the management team of Google Greece for years, leading the commercial launch of YouTube in Greece and Cyprus and has had prior entrepreneurial experience in traditional commerce, while Sagos is a passionate agronomist with deep knowledge in agricultural production and a business background as he was running a seeds trading family business. Parianos is the owner and CEO of McCann Athens and has spent more than 30 years as a senior leader in the advertising industry.
Wikifarmer’s library and marketplace has already been visited by 12 million visitors from more than 200 countries while 30,000 products have been uploaded by farmers. More than 5,000 buyers - including food processing units (FMCGs, Food services, etc), Wholesalers/ Importers, Retail Stores and Hotels/Restaurants - have purchased a product directly from a farm.
The investment will be used to expand the educational content to 20 languages and to enhance Wikifarmer’s marketplace presence in Greece, Italy, France and Spain, with the objective to create a Mediterranean hub of farmers that will attract buyers from all over the world, establishing the platform in a leading place globally.
Sagos said: “We want to democratize agriculture, give farmers around the world the chance to learn new things and thus the opportunity to grow their capabilities, their crops, their earnings. This is the only way forward to make this sector more sustainable and feed the growing world population.”
Ilias Sousis, mentioned regarding the raise: “I am thrilled that a group of very important and sustainability-conscious world-class investors are sharing our vision and efforts to solve some of the biggest pain points that have troubled the sector of agriculture for hundreds of years now.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005694/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
